Literature DB >> 22057136

Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.

Shengqian Xu1, Yu Wang, Jingqiu Lu, Jianhua Xu.   

Abstract

Osteoporosis represents an important cause of morbidity in adult rheumatoid arthritis (RA) patients who exhibit increased fracture risk. It is thought that osteoclast and its dysfunction which mediated by many cytokines are the principal pathogenesis of this bone disease, although the mechanisms are still not fully understood. Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL) have been revealed in the pathogenesis of primary osteoporosis and other metabolic bone diseases. Thus, the aim of this study was to investigate the possible role of the OPG/RANKL system in RA-related bone loss. A total of 64 Chinese patients with RA and 60 healthy control subjects were involved. Serum levels of OPG and RANKL were measured by ELISA. BMD of nondominant forearm, lumbar spine(L(1-4)) and proximal femur, including femoral neck, Wards triangle, greater trochanter were assessed using dual-energy X-ray absorptiometry. RA patients had a higher incidence of osteoporosis (23/64, 35.9%) than that in healthy controls (9/60, 15.0%) (P < 0.0001). They displayed lower BMD values than controls at positions of all detected region. Compared with healthy controls, RA group showed significantly higher serum levels of RANKL (48.4 ± 12.5 vs. 23.0 ± 11.2 pmol/l, P < 0.0001), lower serum levels of OPG (106.2 ± 40.6 vs. 231.6 ± 65.6 pg/ml, P < 0.0001), and OPG/RANKL ratio (2.4 ± 0.7 vs. 7.0 ± 1.1, P < 0.0001). Multiple linear regression analysis revealed that in RA group, plasma rheumatoid factor concentration (β = -0.187, P = 0.031), swollen joint count (β = 0.567, P = 0.029), BMD at forearm (β = 0.324, P = 0.002), femoral Wards triangle (β = 0.370, P < 0.0001), and lumbar spine (β = 0.313, P = 0.003) were the contributors for serum OPG (R ( 2 ) = 0.718, P < 0.0001). Age (β = 0.241, P = 0.042) and BMD at femoral Wards triangle (β = -0.441, P < 0.0001) and lumbar spine (β = -0.320, P = 0.013) were the determinants for serum RANKL (R ( 2 ) = 0.616, P < 0.0001), while swollen joint count (β = 1.029, P = 0.019) and BMD at femoral neck (β = 0.285, P = 0.042) for serum OPG/RANKL ratio (R ( 2 ) = 0.279, P < 0.011). Analysis of logistic regression showed age (P = 0.004, OR = 1.156, 95% CI: 1.047-1.276) and the level of C-reactive protein (P = 0.028, OR = 1.019, CI 95%: 1.002-1.036) in peripheral blood of RA were the risk factors for the occurrence of osteoporosis in RA, while OPG/RANKL ratio (P = 0.007, OR = 0.035, CI 95%: 0.003-0.400) was the unique protective factor. These data suggest that, in Chinese RA patients, an altered modulation of the OPG/RANKL system resulting in increased RANKL and decreased OPG in peripheral blood, could contribute to the bone loss characteristic and the generation of osteoporosis in these patients. Changes of ratio of OPG/RANKL might be a protective mechanism against the accelerated bone loss in RA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057136     DOI: 10.1007/s00296-011-2175-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

Review 1.  Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis.

Authors:  E M Gravallese; S R Goldring
Journal:  Arthritis Rheum       Date:  2000-10

2.  Diagnostic criteria for primary osteoporosis: year 2000 revision.

Authors:  H Orimo; Y Hayashi; M Fukunaga; T Sone; S Fujiwara; M Shiraki; K Kushida; S Miyamoto; S Soen; J Nishimura; Y Oh-Hashi; T Hosoi; I Gorai; H Tanaka; T Igai; H Kishimoto
Journal:  J Bone Miner Metab       Date:  2001       Impact factor: 2.626

3.  Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.

Authors:  S Kotake; N Udagawa; M Hakoda; M Mogi; K Yano; E Tsuda; K Takahashi; T Furuya; S Ishiyama; K J Kim; S Saito; T Nishikawa; N Takahashi; A Togari; T Tomatsu; T Suda; N Kamatani
Journal:  Arthritis Rheum       Date:  2001-05

Review 4.  The diagnostic criteria for primary osteoporosis and the incidence of osteoporosis in China.

Authors:  Zhonghou Liu; Junhong Piao; Lianping Pang; Xiang Qing; Su Nan; Zi'ang Pan; Yichao Guo; Xiaohong Wang; Fangfang Li; Jingping Liu; Xiaoguang Cheng
Journal:  J Bone Miner Metab       Date:  2002       Impact factor: 2.626

Review 5.  Minireview: the OPG/RANKL/RANK system.

Authors:  S Khosla
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

6.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

7.  The effect of a single dose of osteoprotegerin in postmenopausal women.

Authors:  P J Bekker; D Holloway; A Nakanishi; M Arrighi; P T Leese; C R Dunstan
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

8.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Authors:  A Mizuno; N Amizuka; K Irie; A Murakami; N Fujise; T Kanno; Y Sato; N Nakagawa; H Yasuda; S Mochizuki; T Gomibuchi; K Yano; N Shima; N Washida; E Tsuda; T Morinaga; K Higashio; H Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

9.  Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.

Authors:  P Oelzner; S Franke; G Lehmann; T Eidner; A Müller; G Wolf; G Hein
Journal:  Clin Rheumatol       Date:  2007-05-31       Impact factor: 2.980

10.  TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Authors:  B R Wong; R Josien; S Y Lee; B Sauter; H L Li; R M Steinman; Y Choi
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

View more
  40 in total

Review 1.  Osteoarthritis and osteoporosis: what is the overlap?

Authors:  Irene E M Bultink; Willem F Lems
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 2.  Control of autoimmune inflammation by celastrol, a natural triterpenoid.

Authors:  Shivaprasad H Venkatesha; Steven Dudics; Brian Astry; Kamal D Moudgil
Journal:  Pathog Dis       Date:  2016-07-11       Impact factor: 3.166

Review 3.  Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Peng Wang; Si Li; Li-Na Liu; Tian-Tian Lv; Xiao-Mei Li; Xiang-Pei Li; Hai-Feng Pan
Journal:  Clin Rheumatol       Date:  2017-07-11       Impact factor: 2.980

4.  Correlation between hand bone mineral density and joint destruction in established rheumatoid arthritis.

Authors:  Takeshi Mochizuki; Koichiro Yano; Katsunori Ikari; Ryo Hiroshima; Yu Sakuma; Shigeki Momohara
Journal:  J Orthop       Date:  2017-08-02

5.  Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.

Authors:  Xuetong Wang; Cuili Ma; Ping Li; Feng Zhao; Liqi Bi
Journal:  Clin Rheumatol       Date:  2017-05-04       Impact factor: 2.980

6.  Association between rheumatoid arthritics and osteoporosis among Chinese men, a community based study.

Authors:  Hui-Hong Piao; Ke-Qin Zhang; Zi-Hui Tang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

Review 8.  Prevention and treatment of bone changes associated with exposure to glucocorticoids.

Authors:  Amy H Warriner; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 9.  Can bone loss in rheumatoid arthritis be prevented?

Authors:  M Vis; M Güler-Yüksel; W F Lems
Journal:  Osteoporos Int       Date:  2013-06-18       Impact factor: 4.507

10.  Dual X-Ray Absorptiometry Whole Body Composition of Bone Tissue in Rheumatoid Arthritis - a Cross-Sectional Study.

Authors:  Claudiu Popescu; Violeta Bojinca; Daniela Opris; Ruxandra Ionescu
Journal:  Maedica (Buchar)       Date:  2015-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.